PORTABLE DNA TESTING BUSINESS PLAN

I. Executive Summary

Company Description

Founded to reflect rapid, mobile genetic service delivery, the company name draws from the words for genes and movement to signal on-site DNA analysis. It is a U.S.-based mobile DNA analysis provider launching in 2026, operating in the genomics and diagnostics sector. The business delivers portable, state-of-the-art sequencing and interpretation on-site via a fleet of certified practitioners to healthcare, agriculture, and corporate wellness clients. One line: we bring clinically actionable genetic data directly to decision-makers.

The company offers fee-for-service, rapid-turnaround genetic testing and real-time advisory for high-stakes environments where immediate decisions matter. Core activities include client intake, on-site sample collection, portable sequencing, secure data transmission, and practitioner-led interpretation. Competitive edges are mobility, certified staff, and reduced logistical delay compared with traditional labs. Short-term goals: commence operations and prove the model in target verticals in 2026. Long-term goals: scale the mobile workforce and expand service coverage nationally. One line: we scale impact by growing a reliable network of mobile professionals.

Problem

Professional customers lack immediate, on-location genetic insights. Traditional DNA testing depends on centralized labs and slow logistics, causing multi-week delays that impair time-sensitive decisions in oncology, infectious disease screening, livestock management, and wellness consultations. Those delays force conservative clinical actions, repeat sampling, higher sample-transport costs, reduced farm uptime, and lost revenue.

Existing solutions are underserved: central labs optimize throughput, not speed at point of care, and current rapid alternatives either lack clinical-grade accuracy or require fixed-site investments. The result: clinicians, inspectors, and wellness professionals cannot act during critical windows, creating a clear need for reliable, mobile, same-day genetic results. One line: slower testing directly harms outcomes, operations, and revenue.

Solution

We solve slow, lab-dependent DNA testing by bringing compact, state-of-the-art sequencers and certified practitioners directly to clinics, corporate sites, and agricultural fields, eliminating weeks of shipping and centralized processing. Results are delivered in hours, enabling time-sensitive clinical, workplace, and field decisions. One-liner: actionable genetic insights on-site, same day.

Our service pairs portable sequencing kits with a proprietary secure reporting and interpretation platform and a trained mobile team of 12 mobile practitioners in 2026, supporting clinical rapid diagnostics, workplace screening programs, and crop/soil genetic assessment without cold-chain logistics.

Mission Statement

We deliver lab-accurate genetic insights delivered on-site to professionals in healthcare, agriculture, and wellness, removing time and location barriers to DNA analysis. We commit to rapid, data-driven results through portable technology and a dedicated mobile workforce, improving lives and operational efficiency across the United States. We aim to set the standard for reliable, on-demand diagnostics that guide better decisions and measurable outcomes.

Key Success Factors

These factors determine operational performance and financial sustainability; one-liner: hit utilization targets, keep tech current, stay compliant, diversify revenue, and reach breakeven on schedule.

• 60% practitioner utilization for healthcare screeners in year one to drive revenue and capacity efficiency.
• Strategic device and bioinformatics partnerships to maintain state-of-the-art testing accuracy and speed.
• Strict CLIA and HIPAA compliance to build trust with professional clients and avoid regulatory penalties.
• Multi-sector revenue model to stabilize cash flow and enable growth across clinical, research, and consumer channels.
• Breakeven by February 2028 with active cash management to secure long-term sustainability and investor confidence.

Financial Summary

Brief financial snapshot for the Executive Summary showing launch-year metrics, near-term profitability, and key capital needs.

The 2026 launch requires $550,000 in capital expenditures (devices and vehicles); projected payback is 49 months, minimum cash reaches -$1,160,000 (Jan-28), and breakeven is forecast for Feb-28.

Overall outlook: the business reaches EBITDA profitability in 2028 and scales to $6,953,000 EBITDA by 2030 under current assumptions.

Funding Requirements

We require $1,160,000 to fund capital expenditures, setup, training, compliance, and working capital through breakeven (Feb-28).

Financial highlights: 2026 EBITDA -$703,000; profitability in 2028 with EBITDA $435,000; 2030 EBITDA $6,953,000; 123 mobile practitioners; year‑one pricing $150 (screening) and $250 (corporate); ROE 8.36; IRR 0.03%; 2026 capex $550,000; 49‑month payback.